Background: Anaplastic lymphoma kinase (ALK) inhibition using crizotinib has become the standard of care in advanced ALK-rearranged non-small cell lung cancer (NSCLC), but the treatment outcomes and duration of response vary widely. Echinoderm microtubule-associated protein-like 4 (EML4)-ALK is the most common translocation, and the fusion variants show different sensitivity to crizotinib in vitro. However, there are only limited data on the specific EML4-ALK variants and clinical responses of patients to various ALK inhibitors.
Introduction
Genetic alterations in the anaplastic lymphoma kinase (ALK) gene occur in 2%-9% of non-small cell lung cancers (NSCLCs) [1] [2] [3] . Small-molecule tyrosine kinase inhibitors have been developed for ALK-rearranged NSCLC [1, 4] . Crizotinib is the first generation ALK inhibitor and showed objective response rates (ORRs) of 61%-74%, 2-year overall survival rate (OSR) of 54%, and a median progression-free survival (PFS) of 11 months, which is superior to PFS of standard first-line chemotherapy (7 months) [2, [5] [6] [7] .
Resistance to crizotinib develops within 1 or 2 years after initial treatment via various mechanisms [8, 9] but crizotinib-resistant tumors still depend on ALK for growth and survival and are sensitive to second-generation ALK inhibitors such as ceritinib and alectinib [10, 11] .
The predominant fusion partner in ALK-rearranged NSCLC is echinoderm microtubule-associated protein-like 4 (EML4) [12] . Multiple variants of the EML4-ALK fusion have been identified in NSCLC resulting from a translocation at different fusion points within the EML4 gene, with variant 1 (V1, 33%), variant 2 (V2, 10%), and variants 3a/b (V3a/b, 29%) being the most frequent fusion mutants [13] [14] [15] . All variants have exons 20 through 29 of ALK; this region encodes the entire tyrosine kinase domain [14, 16] . EML4 has an N-terminal coiled-coil region, a basic region, a hydrophobic echinoderm microtubule-associated protein-like protein (HELP) motif, and WD (tryptophan-aspartic acid) repeats [17, 18] . The core HELP-WD region forms a novel tandem atypical bpropeller (TAPE) structure. The EML4 TAPE domain is truncated in many variants, which results in a partial structure that makes the EML4-ALK fusion proteins unstable. EML4-ALK variants 1, 2, 7, and others containing a partial TAPE domain are structurally unstable, whereas variants 3a/b and 5a/b lacking any core part of the TAPE structure are structurally stable in vitro [12, 19, 20] . EML4-ALK variants show differential sensitivity to crizotinib in vitro [21] .
Here, we determined variant genotypes of EML4-ALK in patients with advanced ALK-rearranged NSCLC, and assessed correlations of the specific EML4-ALK variant status with clinical outcomes among the patients treated with various ALK inhibitors.
Patients and methods

Study design
We carried out a retrospective analysis to assess the correlation between the treatment outcomes and EML4-ALK variants in patients with advanced ALK-positive NSCLC treated with ALK inhibitors using the Response Evaluation Criteria in Solid Tumor (RECIST) criteria version 1.1 [22] . None of the patients in this study had been previously treated with ALK-specific inhibitors.
We analyzed the sensitivity to ALK inhibitors in stably EML4-ALK V1-, V2-, V3a-, or V5a-expressing Ba/F3 cells and normal bronchial epithelial BEAS-2B cells transiently expressing one of the variants as well as two NSCLC cell lines (H2228 cells expressing variant 3b; H3122 cells expressing variant 1).
Patients
From June 2011 to August 2015, 1721 ALK-naive patients with advanced NSCLC at Asan Medical Center were tested with the Vysis FISH test to identify an ALK rearrangement [2] . The rearrangement was detected in 182 patients (10.6%). Of those, 113 patients were treated with the ALK inhibitors and had an Eastern Cooperative Oncology Group (ECOG) performance status [23] between 0 and 3. Among 81 enrolled patients who were tissue-available and approved by the institutional review board, 24 were excluded because of poor quality of genomic DNA or insufficient tissue samples, and three were lost to follow up (Figure 1 ). For the 54 enrolled patients, medical records were reviewed to extract clinicopathological data including sex, age, smoking status, diagnoses, therapeutic agents, and survival.
Assessment
Patients confirmed to have the ALK translocation were given one of the ALK inhibitors in clinical-practice or clinical-trial settings. They were assigned to receive oral crizotinib at a dose of 250 mg twice daily, alectinib 600 mg two times daily, or ceritinib 750 mg once a day administered every 4 weeks. The cycle was continued as long as the patients did not have the RECIST version 1.1-defined disease progression, unacceptable toxicity, death, or did not withdraw. Treatment responses were evaluated every two cycles using the RECIST criteria version 1.1. The safety or toxicity profile was evaluated every 2 weeks during the first one or two cycles and then every cycle using the Common Terminology Criteria for Adverse Events version 4.
Statistical analysis
Wilcoxon's rank-sum test and Fisher's exact test were used to assess the association between EML4-ALK variants and the clinicopathological characteristics.
Fisher's exact test was conducted for correlations between EML4-ALK variants and the ORR or disease control rate (DCR). To estimate survival rates and compare the survival distribution, we used the Kaplan-Meier method and log-rank test, respectively. All statistical analyses were carried out in the R software (version 3.1.3, the R Foundation for Statistical Computing, Vienna, Austria). Any P value <0.05 was assumed to indicate a statistically significant difference
Detection of the ALK gene rearrangement in daily practice
An ALK rearrangement was detected by FISH analysis using a breakapart probe specific for the ALK locus in supplementary methods, available at Annals of Oncology online.
Genotyping for ALK-positive patients
The ALK-rearranged patients treated with various ALK inhibitors were subtyped using Peptide nucleic acid-mediated quantitative PCR (qPCR) assay (supplementary methods, available at Annals of Oncology online).
Responses of EML4-ALK variants-expressed cell lines to ALK inhibitors in vitro
To identify the correlation of the response and specific EML4-ALK variant expressed-cell lines treated with various ALK inhibitors, viability assay and ALK kinase assay were determined was determined using the CellTiter-Glo V R Luminescent Cell Viability Assay (Promega, Madison, WI) and the Universal Tyrosine Kinase Assay Kit (MK410; Takara Bio, Pittsburg, PA), respectively (supplementary methods, available at Annals of Oncology online).
Results
Clinicopathological characteristics among the patients
A total of 54 patients with advanced ALK-positive NSCLC were analyzed. Baseline clinicopathological characteristics are showed in supplementary Table S1 , available at Annals of Oncology online. Among the 54 patients, crizotinib was a first-line treatment of 17 patients, second-line for 15, third-line for 8, and fourth-or further-line therapy for 7 patients. Alectinib or ceritinib were a first-line treatment of four patients, third-line for one, and fourth-line for two patients.
Among the 54 patients with the ALK translocation, 51 had an EML4-ALK fusion. EML4-ALK variants 3a/b (24, 44.4%) was the most common group, followed by variants 1 (18, 33.3%) and 2 (6, 11.1%). Of the other six patients with rare ALK translocations, one had EML4-ALK variant seven, and two had novel variants EML4-ALK E14del2;del22A20 and E17;del70A20, which represent long EML4-ALK fusion transcripts similar to variant 7 (Table 1; Figure 1 ). The remaining three patients had an ALK rearrangement with a fusion partner other than EML4. According to the expected stability of EML4-ALK variants [19, 21] , all patients but three harboring other fusion partners of ALK were subdivided into two groups: variants 1/2/others and variants 3a/b. The baseline characteristics were well balanced between the two groups (supplementary Table S2 , available at Annals of Oncology online). Treatment-related adverse events and dose reduction are listed in supplementary Tables S3-S5 , available at Annals of Oncology online. Dose reduction was not related to disease progression (P ¼ 0.767).
Treatment responses among patients with different EML4-ALK variants
Median OS and 2-year OSR of all the enrolled 54 patients were 36 months (95% CI 19 months to not available) and 57.8% (95% CI 42.1-79.3), respectively. Median PFS and 2-year PFS rate (PFSR) were 19 months (95% CI 12 months to not available) and 45.1% (95% CI 27.8-73.1), respectively. Among the patients treated with crizotinib, 2-year PFSR was 76.0% (95% CI 56.8-100) in group EML4-ALK variants 1/2/others versus 26.4% (95% CI 10.5-66.6) in group variants 3a/b (P ¼ 0.034; Figure 2A ). When we included the patients treated with alectinib or ceritinib, 2-year PFSR was 69.0% (95% CI 49.9-95.4) for variants 1/2/others versus 32.7% (95% CI 15.6-68.4) for variants 3a/b (P ¼ 0.108; Figure 2B ). There was no significant difference in OS between the two groups (supplementary Figure S1 , available at Annals of Oncology online). This is probably because the mortality rate was relatively low at the data cutoff (33.3%), and the proportion of patients treated with first line therapy was larger in the variant 3a/ b group than in the variant 1/2/other group (54.2% versus 29.6%, P ¼ 0.094), which implies that the variant 1/2/others group included more heavily treated patients. Seven patients (four patients with variants 1/2/others and three patients with variants 3a/b) underwent re-biopsy among the 23 patients who developed progressive disease. There were no ALK mutations identified in those specimens. In each assessment, an ORR and DCR of group variants 1/2/ others were consistent with a strong response tendency when compared with group variants 3a/b (supplementary Table S6 , available at Annals of Oncology online). Overall, DCR was 100% in group variants 1/2/others and 87.5% in group variants 3a/b when we analyzed all patients treated with crizotinib, alectinib, or ceritinib; this result fell short of statistical significance (P ¼ 0.097; Table 2 ).
Responses of cells with EML4-ALK variants to ALK inhibitors in vitro
To test whether the structural differences among EML4-ALK variants have effects on their kinase activities, we generated a system stably expressing EML4-ALK V1, V2, V3a, or V5a in an IL-3-dependent Ba/F3 cell line [24] , which became IL-3-independent and ALK-dependent for growth. Western blotting analysis detected abundantly Tyr-1604-phosphorylated ALK in Ba/F3 cells expressing V3a or V5a ( Figure 3A) . A kinase assay confirmed greater activities in V3a-or V5a-expressing cells than in V1-or V2-expressing cells ( Figure 3B ). Viability assays were carried out for ALK inhibitors-crizotinib, alectinib, and ceritinib-in the four cell lines, and IC 50 values were determined ( Figure 3C and D). All three ALK inhibitors significantly suppressed the growth of V1-or V2-expressing Ba/F3 cells. Ceritinib and alectinib inhibited the proliferation of these two cell lines with much lower IC 50 values when compared with crizotinib. Nonetheless, V3a-or V5a-expressing cells showed similar resistance to all ALK inhibitors, with IC 50 > 500 nM.
Next, we analyzed the sensitivity to ALK inhibitors among NSCLC cell lines (H3122 cells with EML4-ALK V1 and H2228 cells with EML4-ALK V3b) and normal bronchial epithelial BEAS-2B cells transiently expressing an EML4-ALK variant. H3122 cells showed the highest sensitivity to ALK inhibitors among the cell lines examined; in contrast, H2228 and BEAS-2B cells expressing V3a or V5a exhibited only weak growth inhibition under the influence of ALK inhibitors ( Figure 3E and F) . We analyzed ALK fusion variants in 54 ALK-rearranged NSCLCs, and subdivided them into groups variants 1/2/others (27, 49.9%) and variants 3a/b (24, 44.4%) according to expected stability differences among EML4-ALK variant proteins. Given that group variants 1/2/others has the truncated incomplete tandem atypical propeller EML (TAPE) domain of EML4, whereas group variants 3a/b lacks any part of the TAPE domain [19] , we hypothesized that group variants 1/2/others may have better treatment outcomes than the variants 3a/b group because of protein instability of variants 1/2/others. Our results revealed that PFS is significantly longer in group variants 1/2/others than in group variants 3a/b. The former group also showed a tendency for greater ORR and DCR after treatment with crizotinib, alectinib, or ceritinib. These data suggest that EML4-ALK variants may be an important factor contributing to ALK inhibitor resistance in the large majority of tumors among patients with advanced ALK-rearranged NSCLC.
Our in vitro results on EML4-ALK variant-expressing Ba/F3 and BEAS-2B cells clearly showed that V3a-or V5a-harboring cells are resistant to crizotinib, ceritinib, and alectinib, and show >10-fold higher IC 50 than do V1-or V2-expressing cells. These findings suggest that the "variants 3a/b" group of our patients will not benefit much from ALK signaling inhibition; this problem may be overcome by more potent ALK inhibitors or by combined treatment with other regimens.
Lei et al. reported no correlation between EML4-ALK variants and clinical responses to crizotinib, in contradiction to our data.
They classified EML4-ALK variants into two groups of common variants (V1 and V3a/b, 65.6%) and uncommon variants (V2, V5, V7, and other partner-ALK fusions, 34.6%) [25] . We believe that the reason for the discrepancy is that they did not consider the stability of EML4-ALK variants. While we prepared this manuscript, Yoshida et al. reported that after treatment with crizotinib, PFS of the EML4-ALK V1 group (19 patients, 54%) is superior to that of the non-V1 group (V2, five patients, 14%; V3a/ b, four patients, 12%; other variants, seven patients, 20%) [26] . The difference in PFSR after crizotinib treatment between the V1 and non-V1 groups in that study is much smaller than the difference between groups "variants 1/2/others and variants 3a/b" in our study (a stark difference in the graph, Figure 2 ). This is probably because classification of patients based on the V1 variant results in insufficient stratification of treatment responses. It should be emphasized that the V3a-and V5a-expressing cells did not respond well to treatment with advanced next-generation ALK inhibitors. In spite of a lack of clinical data, these in vitro data suggest that more potent and structurally distinct ALK inhibitors should be developed to target the stable and treatmentresistant EML4-ALK variants.
In conclusion, our findings reveal that there is a subset of ALK rearrangement-positive NSCLCs responding differently to ALK inhibitors according to EML4-ALK variants. The ALK inhibitorresistant patients harboring variants 3a/b represent 44% of our study population. Therefore, stratification of patients with advanced ALK rearrangement-positive NSCLC by the variant-specific genotype should help to predict clinical responses to ALK inhibitors.
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